Dated: February 2, 2009. Carolyn M. Clancy, Director. [FR Doc. E9–2680 Filed 2–9–09; 8:45 am] BILLING CODE 4160–90–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Committee to the Director, Centers for Disease Control and Prevention (ACD, CDC)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the CDC announces the following meeting of the aforementioned committee:

Time and Date: 3 p.m.–4:30 p.m., February 24, 2009.

Place: The teleconference call will originate at the CDC. For details on accessing the teleconference is located in the supplementary information.

Status: Open to the public, teleconference access limited only by availability of telephone ports.

Purpose[•] The committee will provide advice to the CDC Director on strategic and other broad issues facing CDC.

Matters to be Discussed: The Advisory Committee to the Director will discuss and decide on recommendations from its Ethics Subcommittee, National Biosurveillance Advisory Subcommittee, and Budget Workgroup. The Ethics Subcommittee will make recommendations on using travel restrictions for individuals with infectious illnesses. The Ethics Subcommittee will also discuss a draft charge that clearly articulates the ethical foundation for focusing on health protection activities and examining the social determinants of health. The National Biosurveillance Advisory Subcommittee will seek approval on recommendations for latitude to share specific points with key members of the new administration. The Budget Workgroup will provide recommendations around principles for change, in terms of the budget and the budget structure and process for the CDC.

Agenda items are subject to change as priorities dictate.

Supplementary Information: This conference call is scheduled to begin at 3 p.m. Eastern Standard Time. To participate in the teleconference, please dial 1 (888) 323–9787 and enter conference code 4735949.

Contact Person for More Information: Brad Perkins, M.D., M.B.A., Executive Officer, ACD, CDC, 1600 Clifton Road, NE., M/S D– 14, Atlanta, Georgia 30333. *Telephone:* (404) 639–7000.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the CDC and the Agency for Toxic Substances and Disease Registry. Dated: February 3, 2009. **Elaine L. Baker,** Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC). [FR Doc. E9–2805 Filed 2–9–09; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Assessing the Accuracy of Self-Report of HIV Testing Behavior, Program Announcement Number (PA) 09–002

In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting.

Time and Date: 8 a.m.–5 p.m., March 20, 2009 (Closed).

Place: Sheraton Gateway Hotel, Atlanta Airport, 1900 Sullivan Road, Atlanta, GA 30337, Telephone (770) 997–1100.

Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of "Assessing the Accuracy of Self-Report of HIV Testing Behavior, Program Announcement Number (PA) 09–002."

Contact Person for More Information: Gregory Anderson, M.P.H., M.S., Scientific Review Administrator, Strategic Science and Program Unit, Office of the Director, Coordinating Center for Infectious Diseases, CDC, 1600 Clifton Road, Mailstop E–60, Atlanta, GA 30333, *Telephone:* (404) 498– 2275.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: February 3, 2009.

Elaine L. Baker,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. E9-2803 Filed 2-9-09; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2008-D-0339]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Guidance for Industry on Updating Labeling for Susceptibility Test Information in Systemic Antibacterial Drug Products and Antimicrobial Susceptibility Testing Devices

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. **DATES:** Fax written comments on the collection of information by March 12, 2009.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-6974, or e-mailed to oira submission@omb.eop.gov. All comments should be identified with the OMB control number 0910-NEW and title "Guidance for Industry on Updating Labeling for Susceptibility Test Information in Systemic Antibacterial Drug Products and Antimicrobial Susceptibility Testing Devices." Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Elizabeth Berbakos, Office of Information Management (HFA–710), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–796–3792.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Guidance for Industry on Updating Labeling for Susceptibility Test Information in Systemic Antibacterial Drug Products and Antimicrobial Susceptibility Testing Devices

In the **Federal Register** of June 12, 2008 (73 FR 33438), FDA announced the availability of a draft guidance for